QIAGEN N.V.
514 articles about QIAGEN N.V.
-
QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook
8/8/2023
QIAGEN announced results for the second quarter and first half of 2023.
-
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
8/7/2023
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit).
-
Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement
7/26/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
-
QIAGEN N.V. to release results for Q2 2023 and hold webcast
7/24/2023
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.
-
QIAGEN expands range of digital PCR kits and services for the biopharma industry
7/18/2023
QIAGEN announced the expansion of its digital PCR offering for the development of cell and gene therapies in the biopharma industry.
-
FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
6/20/2023
QIAGEN announced that the U.S. Federal Bureau of Investigation has approved its ForenSeq® MainstAY workflow.
-
QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening
6/15/2023
QIAGEN welcomes the publication of a new, systematic review highlighting the unique value of its proprietary tuberculosis testing technology.
-
Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing
6/13/2023
QIAGEN announced that its variant interpretation and reporting software, QIAGEN Clinical Insight Interpret, is being deployed as a part of a national initiative in Denmark to offer sequencing-based solutions for cancer patients.
-
QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
5/3/2023
QIAGEN announced that it welcomed the U.S. Preventive Services Task Force reaffirming a previously issued recommendation for latent tuberculosis infection screening by primary care physicians in populations at increased risk.
-
QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio
5/3/2023
Net sales for Q1 2023 declined 23% to $485 million from Q1 2022, which was marked by very strong COVID-19 sales contributions.
-
QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
4/24/2023
QIAGEN announced that its QIAstat-Dx syndromic testing solution is expected to be available soon for use in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a single patient sample.
-
QIAGEN announces expansion of Supervisory BoardSteve Rusckowski has joined Supervisory Board and will stand for election at Annual General Meeting in June 2023
4/20/2023
QIAGEN announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting scheduled for June 22, 2023.
-
QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
4/14/2023
QIAGEN announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other diseases to turn cell-free DNA liquid-biopsy samples into libraries ready for next-generation sequencing in less than eight hours.
-
QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissions
3/27/2023
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals.
-
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
3/13/2023
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission.
-
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
3/9/2023
QIAGEN N.V. announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia.
-
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
2/7/2023
QIAGEN N.V. announced results for the fourth quarter and full-year 2022. Net sales for Q4 2022 declined 14% to $498 million from Q4 2021.
-
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
1/17/2023
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.
-
Helix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary Diseases
1/5/2023
Helix, the leading population genomics and viral surveillance company in the nation, announced a global strategic partnership with QIAGEN N.V., the leading global provider of Sample to Insight solutions, to jointly develop companion diagnostics for hereditary diseases.
-
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
11/7/2022
QIAGEN N.V. announced results for the third quarter of 2022 and first nine months of 2022, and increased the outlook for full-year 2022.